Viyash Scientific Limited announced its financial results for the second quarter and first half of fiscal year 2027. The company reported a robust 17.8% increase in revenue for H1 FY27, reaching ₹19,343 million. Profit after tax also saw a substantial jump of 49.4% to ₹1,639 million. The results highlight strategic growth, including the acquisition of BioForLife in Italy and investments in new oncology and companion animal manufacturing capabilities.
Viyash Scientific Q2 and H1 FY27 Financial Highlights
Viyash Scientific Limited has released its financial performance for the quarter and half-year ended November 13, 2026. The company demonstrated strong growth across key financial metrics, underscoring its strategic initiatives and operational efficiency.
H1 FY27 Performance
For the first half of fiscal year 2027, Viyash Scientific reported total revenues of ₹19,343 million, marking a significant year-on-year increase of 17.8%. EBITDA stood at ₹4,124 million, up 29.9% year-on-year. The EBITDA margin was reported at 21.3%. The Net Debt to LTM EBITDA ratio was a healthy 0.0x, with Net Debt at ₹261 million.
Q2 FY27 Performance
In the second quarter of FY27, revenues amounted to ₹9,879 million, a 16.2% increase compared to the same quarter in the previous year. EBITDA for Q2 FY27 was ₹2,077 million, up 10.3% year-on-year. The EBITDA margin was 21.0%. The Net Debt to LTM EBITDA remained at 0.0x.
Consolidated Financials Snapshot
The consolidated financials reveal a revenue of ₹9,879 million for Q2 FY27, with a 16.2% YoY growth. Gross Margin stood at 53.7%. EBITDA for the quarter was ₹2,077 million, showing a 10.3% YoY increase. Earnings After Tax for Q2 FY27 were ₹847 million, a 16.1% increase from the prior year. For H1 FY27, Revenue from Operations reached ₹19,343 million (17.8% YoY growth), and Earnings After Tax were ₹1,639 million (49.4% YoY growth).
Strategic Updates
The company highlighted key strategic developments including the acquisition of BioForLife in Italy, aimed at strengthening its companion animal platform. Viyash Scientific is also investing in new oncology capabilities, an in-house companion animal manufacturing facility, and expanding its API capacity. These initiatives are part of its focus on disciplined execution, R&D-led growth, and sustainable value creation.
Source: BSE
